Blueshift Asset Management LLC Buys Shares of 4,284 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Blueshift Asset Management LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,284 shares of the company’s stock, valued at approximately $494,000.

Other large investors have also added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences during the second quarter valued at $28,000. Innealta Capital LLC bought a new position in Neurocrine Biosciences during the 2nd quarter worth $30,000. New Covenant Trust Company N.A. bought a new position in Neurocrine Biosciences during the 1st quarter worth $32,000. EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $35,000. Finally, Blue Trust Inc. increased its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 1.0 %

NBIX stock opened at $126.59 on Thursday. The stock’s 50 day moving average is $118.97 and its 200-day moving average is $131.71. Neurocrine Biosciences, Inc. has a twelve month low of $110.81 and a twelve month high of $157.98. The firm has a market capitalization of $12.82 billion, a PE ratio of 33.94 and a beta of 0.35.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Jefferies Financial Group upped their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research note on Monday, August 19th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Barclays cut their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Finally, StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.